|
1
|
Graceffa P, Melatti P, Dioguardi A, Callari C, Cartabellotta F, Granata A. Hematic Peri-gastric Collection Post-LSG: What About Endoscopic Internal Drainage? Obes Surg 2024; 34:2001-2002. [PMID: 38499944 DOI: 10.1007/s11695-024-07166-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 03/07/2024] [Accepted: 03/07/2024] [Indexed: 03/20/2024]
Affiliation(s)
- Pietro Graceffa
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy.
| | - Piera Melatti
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy
| | - Angelo Dioguardi
- Center of Excellence in Bariatric Surgery, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy
| | - Cosimo Callari
- Center of Excellence in Bariatric Surgery, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy
| | - Fabio Cartabellotta
- Department of Internal Medicine, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy
| | - Antonino Granata
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, Postal Code: 90123, Palermo, Italy
| |
Collapse
|
|
2
|
Graceffa P, Melatti P, Callari C, Granata A. Endoluminal Rescue Management in a Complete Dehiscence of the Gastric Sleeve Suture Line. Obes Surg 2023; 33:3710-3711. [PMID: 37782405 DOI: 10.1007/s11695-023-06838-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 08/22/2023] [Accepted: 09/15/2023] [Indexed: 10/03/2023]
Affiliation(s)
- Pietro Graceffa
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, 90123, Palermo, Italy.
| | - Piera Melatti
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, 90123, Palermo, Italy
| | - Cosimo Callari
- Center of Excellence in Bariatric Surgery, Buccheri La Ferla Hospital, 90123, Palermo, Italy
| | - Antonino Granata
- Interventional Endoscopic Unit, Buccheri La Ferla Hospital, 90123, Palermo, Italy
| |
Collapse
|
|
3
|
Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Therap Adv Gastroenterol 2021; 14:17562848211031420. [PMID: 34349836 PMCID: PMC8295962 DOI: 10.1177/17562848211031420] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 06/22/2021] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lacking. We aimed to compare the effectiveness and tolerability between adalimumab originator, ABP501 and SB5 biosimilars in patients with IBD in the short term (after induction and after 6 months of treatment) through a propensity score-weighted multicenter cohort study. METHODS We included 156 patients with IBD, 69 patients with ulcerative colitis and 87 patients with Crohn's disease (CD) receiving ABP501 or SB5 biosimilars from January 2019 to April 2020 for moderate-to-severe disease. For comparison, a group of age- and sex-matched patients treated with adalimumab originator was used. We collected clinical and biochemical data after induction and at 6 months of treatment. Endoscopic data were recorded only at baseline. RESULTS Overall, clinical benefit was achieved by 86.4% and 85.3% after induction and at 6 months, respectively, without a statistically significant difference between the three treatment groups (p = 0.68 and p = 0.46). However, after induction, we found significant differences between the two types of the disease (ulcerative colitis or CD, p = 0.004), with a greater clinical benefit achieved by patients with CD. Also, the therapeutic optimization rate between the three drugs was not statistically significant different (p = 0.30). All treatments showed a good safety profile, with only 10 patients who needed to stop therapy because of adverse events. CONCLUSION Adalimumab biosimilars seem to be as effective and safe as the originator in patients with IBD. Surely, they represent a great opportunity to reduce the costs of biological therapies, however larger and longer real-life studies are necessary.
Collapse
Affiliation(s)
| | | | - Cristina Canova
- Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy
| | - Giulia Barbieri
- Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy
| | - Renato Sablich
- Gastroenterology Unit, Santa Maria degli Angeli Hospital, Pordenone, Friuli-Venezia Giulia, Italy
| | - Maria Teresa Urbano
- Gastroenterology Unit, Santa Maria degli Angeli Hospital, Pordenone, Friuli-Venezia Giulia, Italy
| | - Lorenzo Bertani
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Francesco Costa
- Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
| | - Giorgia Bodini
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy
| | - Maria Giulia Demarzo
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy
| | - Antonio Ferronato
- Endoscopy Unit, Alto Vicentino Hospital, AULSS7 Pedemontana, Santorso, Veneto, Italy
| | - Andrea Buda
- Gastroenterology Unit, Hospital Feltre, Italy
| | - Piera Melatti
- Department of Surgery, Oncology, Gastroenterology, University of Padua, Padua, Veneto, Italy
| | - Davide Massimi
- Department of Surgery, Oncology, Gastroenterology, University of Padua, Padua, Veneto, Italy
| | | | | |
Collapse
|